MSCE

Cathie Biga is New American College of Cardiology President

Retrieved on: 
Monday, April 8, 2024
College, FACC, Culture, Practice management, NCDR, Science, Trustee, Knowledge, History, Registry, Health policy, MSN, American College, MPH, Multimedia, ACC, Health, MSCE, Nursing

ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president. She will serve a one-year term representing over 56,000 cardiovascular care team members around the world and leading the cardiovascular organization in its mission to transform cardiovascular care and improve heart health for all.

Key Points: 
  • ATLANTA, April 8, 2024 /PRNewswire/ -- Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization's first non-physician president.
  • "The concept of 'standing on the shoulders of giants' is often referenced when talking about leadership changes and transformation over time.
  • She's been a member of the ACC Board of Trustees for six years, most recently serving as vice president.
  • The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all.

Reproductive Medicine Associates Opens New State-of-the-Art Fertility Center and IVF Lab in Bellevue, Expanding Access to Fertility Care in Washington State

Retrieved on: 
Wednesday, March 13, 2024
Science, Practice Management, Research, Managed Care, General Health, Health, Hospitals, Other Health, Seattle metropolitan area, Infertility, FACOG, Patient, IVF, Interstate 405, Reproductive medicine, Fertility, IUI, MD, IVI, RMA, Medical director, Interstate Highway System, PGT, MSCE, Birth control

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.

Key Points: 
  • Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.
  • The clinic is RMA’s second location in Washington state, after Seattle, and adds to an extensive network of more than sixty RMA clinics across the United States.
  • “We’re committed to expanding access to cutting-edge fertility care for the roughly 1 in 5 Americans who struggle with infertility,” said Lynn Mason, CEO of IVI RMA America.
  • The center will also offer family planning resources and options for LGBTQ+ individuals and fertility preservation treatments for those individuals with autoimmune diseases or cancer diagnoses.

The Vertex Companies, LLC Acquires TriLogix Consulting, LLC

Retrieved on: 
Wednesday, March 27, 2024
Culture, Risk management, Learning, Partnership, Acquisition, CPM, General contractor, JD, MSCE

WEYMOUTH, Mass., March 27, 2024 /PRNewswire/ -- The Vertex Companies, LLC ("Vertex") is pleased to announce the acquisition of TriLogix Consulting, LLC ("TriLogix"), a highly respected construction claims, scheduling, and risk management firm that is based out of New Jersey and offers its services throughout the United States. TriLogix's team brings decades of consulting and testifying experience and its staff includes professional engineers, CPM scheduling experts, and professionals experienced in supporting the management of complex construction projects.

Key Points: 
  • The Vertex Companies, LLC ("Vertex") is pleased to announce the acquisition of TriLogix Consulting, LLC
    "We couldn't be more excited to welcome TriLogix to the Vertex team because both firms embrace a culture that maximizes urgency, learning, value, and synergies," said Bill McConnell, PE, MSCE, JD, Chairman of the Board.
  • Vertex continues to seek acquisitions that add exceptional talent, complementary employee-focused cultures, and a deep commitment to clients.
  • Jeff Picard, Chief Strategy Officer of Vertex said, "The addition of the amazing team at TriLogix represents our continued commitment to better outcomes for our clients, colleagues, and communities."
  • Hugh Coyle, Managing Director of Vertex's Project Advisory team noted, "We are excited to welcome the TriLogix team to Vertex.

CHOP Researchers Find Branched Chain Amino Acid Supplementation May Aid in Concussion Recovery

Retrieved on: 
Tuesday, March 19, 2024
Online, Research, Mind, Stroke, Concussion, Assistant, CHOP, Critical Care Medicine (journal), Patient, DSM-IV codes, Journal, Anesthesiology, Leucine, Dana Foundation, Health, University, Doctor of Philosophy, MD, Human, Valine, Critical care, Adolescence, Isoleucine, Veteran, Clinical trial, BCAA, Pediatrics, Traumatic brain injury, National Institutes of Health, Hospital, Head injury, Randomized controlled trial, Safety, Ageing, HIT, Bangladesh Technical Education Board, Medicine, Children's Hospital of Philadelphia, MSCE, Dietary supplement

PHILADELPHIA, March 19, 2024 /PRNewswire/ -- In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists from the Minds Matter Concussion Frontier Program at Children's Hospital of Philadelphia (CHOP) have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity. The findings were published online by the Journal of Neurotrauma.

Key Points: 
  • The mainstay of treatment remains symptom management with temporary modification of cognitive and physical activity and over the counter medication.
  • Although active rehabilitation strategies have shown promise for improving recovery time, including aerobic, vestibular, and vision interventions, these can be time and labor intensive.
  • To date, no targeted pharmacologic intervention to improve clinical outcomes in concussion has been evaluated in humans.
  • However, prior to this study, no human studies involving adolescents and young adults have assessed the potential benefits of this formulation of BCAAs as a specific treatment to aid in concussion recovery.

Largest Ever Real-World Evidence Study of Ambulatory Cardiac Monitoring Demonstrates Clinical Superiority of iRhythm's Zio Long-Term Continuous Monitoring Service

Retrieved on: 
Friday, January 5, 2024
AEM, MAS, Economics, ECG, Probability, Medical Center, Research, ACMS, Master of Science, LTCM, National Association, Health, ACM, Arrhythmia, Northwestern University, Medicare, MCT, American College, Manuscript, Patient, Diagnosis, Medicine, MSCE, AHJ, Medical device

The retrospective study of almost 300,000 patients makes CAMELOT the largest published real-world comparative effectiveness analysis of ambulatory cardiac monitoring.

Key Points: 
  • The retrospective study of almost 300,000 patients makes CAMELOT the largest published real-world comparative effectiveness analysis of ambulatory cardiac monitoring.
  • “Our findings reveal significant variation in selection of monitoring devices, which can be influenced by patient characteristics and other factors.
  • Holter, AEM, MCT, and non-iRhythm LTCM were 50%, 42%, 33%, and 23% less likely to achieve clinical arrhythmia encounter diagnosis compared to the Zio LTCM service, respectively.
  • Non-iRhythm LTCMs were 3.7 times more likely to result in a retest than the Zio LTCM service.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Diarrhea, DSM-IV codes, Cannabidiol, Lethargy, Partnership, Constipation, Clobazam, Aes, Lamotrigine, Caregiver, Principal, Research, LGS, TID, DEE, ASMS, Medication, Data, Physician, Somnolence, MD, Doctor of Philosophy, DS, SAE, Seizure, Combination, Pharmacokinetics, Appetite, Participation, Patient, Diagnosis, Safety, Levetiracetam, MSCE, Pharmaceutical industry

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

Prevent Blindness Joins National Glaucoma Awareness Month in January to Educate the Public and Professionals on the "Silent Thief of Sight"

Retrieved on: 
Wednesday, December 27, 2023
Patient, Community, Glaucoma, NMA, BrightFocus Foundation, Disease, MD, Apple, Web browser, Microsoft PowerPoint, National Medical Association, Visual impairment, Assistant, Social media, Peripheral vision, Television, Safety, MSCE, Paratriathlon, Medical imaging

CHICAGO, Dec. 27, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, is once again participating in January's National Glaucoma Awareness Month to provide patients, care partners, and professionals with a variety of helpful resources to educate on glaucoma, one of the leading causes of blindness in the United States. In addition to a dedicated webpage at PreventBlindness.org/glaucoma, Prevent Blindness offers a variety of downloadable fact sheets, including a listing of glaucoma financial assistance resources, shareable social media graphics in English and Spanish, and educational videos. These awareness month efforts are supported by funding from Glaukos.

Key Points: 
  • Glaucoma is often referred to as the "silent thief of sight," because symptoms can begin gradually, usually affecting peripheral vision first.
  • All Glaucoma Community content is written by professional health writers and reviewed by the Expert Advisory Council for The Glaucoma Community.
  • Program partners for The Glaucoma Community include the BrightFocus Foundation, The Glaucoma Foundation, Glaucoma Research Foundation, and the National Medical Association (NMA) Ophthalmology Section.
  • As part of National Glaucoma Awareness Month, Prevent Blindness will be debuting the new "Focus on Eye Health Patient Story: Glaucoma" video, featuring Prevent Blindness Associate Director of Eye Health Services, Tasha R. Lockridge, sharing her personal journey with glaucoma.

NEA AWARDS GRANTS FOR ECZEMA RESEARCH TOTALING NEARLY $1 MILLION

Retrieved on: 
Tuesday, December 12, 2023
MSN, Research, Attentional bias, Pediatric Dermatology, Dermatitis, Doctor of Pharmacy, RN, Patient, MSCE, NEA, Science, Pedrá, Harvard College, Atopic dermatitis, Health, National Institutes of Health, NIH, University, MPH, Doctor of Philosophy, Quality of life, Bangladesh Technical Education Board, Inflammation, Pharmaceutical industry, Harbor, Nursing, Management, Boston, MD

NOVATO, Calif., Dec. 12, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced the recipients for its 2023 research grants. From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million. NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.  

Key Points: 
  • From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million.
  • NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.
  • With 2023 marking the 20th anniversary of its grantmaking, NEA has invested nearly $4 million since its first grant was awarded in 2004.
  • The 2023 research grants were awarded as follows:
    Champion Research Grant– Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

NCCN Summit Navigates Solutions for Financial and Other Cancer-Related Hardships

Retrieved on: 
Tuesday, December 5, 2023
Disease, Health equity, Cancer Support Community, Senior, DNP, Life, Patient, UAB, CMS, Partnership, Doctor of Philosophy, Mental health, Quality of life, Engagement, Toxicity, National Comprehensive Cancer Network, Mortality, MSS, MSCE, Risk, CSSBB, Health, FCPP, DEI, Estate (law), Durrow healthcare consultancy, Public policy, FACP, NCCN, University of Pennsylvania, Imerman Angels, Social conditioning, ACCC, Leadership Council, Patient navigators, University, Medicare, Diversity, Education, Chief innovation officer, Associate, LCSW, Policy, MMM, Navigation, RN, Breast cancer, LSW, Inclusion, Refugee, Survival, Social work, Wastewater treatment, Pharmaceutical industry, Medical device, Hospital, Management, Nursing, Cancer, MSW, Medicine, MD

PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care. The speakers included patients and advocates, policymakers, health care providers, and health data analysts.

Key Points: 
  • Denlinger
    The summit featured a series of best practice presentations highlighting some of the tools available to assist in various areas of patient navigation.
  • Speakers identified significant financial hardships that can come with cancer care, which can contribute to logistical barriers or issues involving emotional well-being.
  • Navigating a patient through their healthcare coverage and preventing financial ruin from astronomical cancer care costs has grown more complex.
  • NCCN's annual Patient Advocacy Summit follows another recent Oncology Policy Summit where the organization unveiled recommendations for screening health-related social needs ( HRSN ) in cancer care.

PCORI approves $80.5 million for health research using novel approaches to tackle social and clinical care factors that contribute to maternal health inequities

Retrieved on: 
Tuesday, November 28, 2023
Disease, Health equity, PCORI, Black, Research, Depression, Maternal death, Patient-Centered Outcomes Research Institute, Anxiety, Mortality, Patient, Pregnancy, MSCE, Element, Partner, Community, Health, MPH, Mother, Education, CER, Hypertension, Transport, Hispanic, Birth control, Nursing

WASHINGTON, Nov. 28, 2023 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today announced funding awards totaling $80.5 million to support four new, ambitious patient-centered comparative clinical effectiveness research (CER) studies focused on both the health care and social factors that contribute to inequities in maternal morbidity and mortality. The trials are among 30 CER studies and related projects recently approved for PCORI funding.

Key Points: 
  • Recognizing that these challenges are influenced by factors beyond clinical care, these studies will evaluate multicomponent interventions that address both health care and social determinants of health.
  • "The usual approaches to health research and health care have not sufficiently addressed the alarming and worsening national crisis of maternal death and severe illness," said PCORI Executive Director Nakela L. Cook, M.D., MPH.
  • All funding awards were approved pending a business and programmatic review by PCORI staff and the issuance of formal award contracts.
  • With these latest awards, PCORI has invested more than $4.5 billion to fund patient-centered CER and support other projects.